Markets:

Overview

News

Currencies

International

Treasuries

InflaRx N.V. - Common Stock (NQ:IFRX)

1.460 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about InflaRx N.V. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session ↗

June 27, 2022

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 27, 2022

Good morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning!

Via InvestorPlace

Read Why Did Raymond James Slash Price Target On Inflarx ↗

May 13, 2022

Via Benzinga

Analyst Ratings for InflaRx ↗

May 13, 2022

Analysts have provided the following ratings for InflaRx (NASDAQ:IFRX) within the last quarter:

Via Benzinga

InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients ↗

March 31, 2022

Via Benzinga

Epizyme + 20 Stocks Moving In Monday's Pre-Market Session ↗

June 27, 2022

Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday.

Via Benzinga

Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday ↗

June 27, 2022

Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation...

Via Benzinga

Recap: InflaRx Q4 Earnings ↗

March 24, 2022

InflaRx (NASDAQ:IFRX) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease ↗

March 17, 2022

InflaRx N.V. (NASDAQ: IFRX) has

Via Benzinga

Recap: InflaRx Q1 Earnings ↗

May 12, 2022

InflaRx (NASDAQ:IFRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings InflaRx missed estimated earnings by...

Via Benzinga

53 Biggest Movers From Yesterday ↗

April 01, 2022

Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...

Via Benzinga

36 Stocks Moving In Thursday's Mid-Day Session ↗

March 31, 2022

Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 71% to $11.57 after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with...

Via Benzinga

Why InflaRx Shares Are Ripping Higher Thursday ↗

October 28, 2021

InflaRx N.V. (NASDAQ:IFRX)

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 31, 2022

On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

March 25, 2022

Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.

Via Benzinga

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings ↗

March 20, 2022

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...

Via Benzinga

See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition ↗

February 28, 2022

InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small...

Via Benzinga

InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder ↗

November 15, 2021

InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). ...

Via Benzinga

70 Biggest Movers From Friday ↗

November 15, 2021

Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results ↗

October 28, 2021

Toward the end of trading Thursday, the Dow traded up 0.45% to 35,651.09 while the NASDAQ rose 1.21% to 15,420.51. The S&P also rose, gaining 0.83% to 4,589.40. The U.S. has...

Via Benzinga

Topics Stocks

66 Biggest Movers From Yesterday ↗

October 29, 2021

Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...

Via Benzinga

Mid-Day Market Update: Nasdaq Rises Over 1%; Rafael Holdings Shares Slide ↗

October 28, 2021

Midway through trading Thursday, the Dow traded up 0.40% to 35,631.75 while the NASDAQ rose 1.09% to 15,401.19. The S&P also rose, gaining 0.74% to 4,585.17. The U.S. has the...

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021 ↗

October 28, 2021

Upgrades For Boot Barn Holdings Inc (NYSE:

Via Benzinga

Mid-Morning Market Update: Markets Rise; Caterpillar Profit Beats Expectations ↗

October 28, 2021

Following the market opening Thursday, the Dow traded up 0.53% to 35,678.96 while the NASDAQ rose 0.95% to 15,380.23. The S&P also rose, gaining 0.76% to 4,586.39. The U.S....

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

30 Stocks Moving in Thursday's Pre-Market Session ↗

October 28, 2021

Gainers InflaRx N.V. (NASDAQ: IFRX) rose 47.9% to $4.23 in pre-market trading. Raymond James upgraded InflaRx from Outperform to Strong Buy and announced a $14 price target....

Via Benzinga

InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial ↗

October 19, 2021

The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher ↗

October 19, 2021

Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35. The U.S. has...

Via Benzinga

Topics Stocks

Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge ↗

October 19, 2021

Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69. The U.S. has the...

Via Benzinga

Topics Stocks

52 Biggest Movers From Yesterday ↗

October 20, 2021

Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.